Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 27, 2006 Rick Aristotle Munarriz	Select Comfort Sleeps on It Sales soared high, but the bottom line was even dreamier. Select Comfort is a good bargain for investors right now.
The Motley Fool February 12, 2008 Rick Aristotle Munarriz	A Lumpy Mattress Stock Select Comfort shares sank by 31% to a new low, after the company posted disappointing fourth-quarter results.
The Motley Fool October 29, 2007 Mike Kasprzyk	World's Scariest Stock: Select Comfort Select Comfort is a stock that will keep you tossing and turning at night if you're a shareholder. Only in your dreams will this company earn 50% annual returns.
The Motley Fool February 9, 2007 Rick Aristotle Munarriz	Counting Cheap at Select Comfort The Sleep Number bed maker's got the market's number. Shares inched higher after a better-than-expected fourth-quarter report.
The Motley Fool July 26, 2007 Rick Aristotle Munarriz	Wake Up, Select Comfort! Air mattress maker Select Comfort has another tough quarter. Perhaps they were caught sleeping as competitors moved ahead.
The Motley Fool September 14, 2005 Rich Smith	Select Short Squeeze Select Comfort released bad news after market close on Tuesday. That is to say, bad news if you're one of the many people who have sold 14% of the company's float short.
The Motley Fool February 9, 2009 Devon Rackle	Liquidity's Shockingly Bad Quarter Liquidity Services, an online marketplace for wholesale surplus and salvage assets such as consumer electronics, apparel, and technology hardware, extends its dominance of its niche despite a bad quarter.
The Motley Fool December 27, 2006 Rick Aristotle Munarriz	Previewing 2007: Select Comfort If Select Comfort is able to get back into its groove, shares of the company will be a good value at today's prices.
The Motley Fool December 19, 2011 Brian Orelli	ARIAD's Prolific 2011 The biotech is doing something right.
The Motley Fool May 30, 2007 Rich Smith	Foolish Forecast: Growth at Conn's? The retailer is set to report its fiscal first-quarter 2008 earnings results. Investors, here is what you can expect to see.
The Motley Fool April 26, 2007 Rick Aristotle Munarriz	Your Sleep Number Is Going Down The Sleep Number bed maker weakens in its latest quarter. Investors, take note.
The Motley Fool February 1, 2006 Rick Aristotle Munarriz	Select Comfort's Good Night's Sleep The Sleep Number bed maker keeps turning the knob higher with a strong 2005 and promising 2006. Investors, take note.
The Motley Fool December 14, 2005 Rick Aristotle Munarriz	Select Comfort's Wide Awake The bed maker announced that favorable trends over the holiday shopping season make it comfortable delivering full-year earnings guidance of $1.05 to $1.08 per share, "with some upside potential."
The Motley Fool January 11, 2005 Rick Aristotle Munarriz	Know Your Sleep Number Select Comfort's recently sleepy slump may turn into a welcome awakening. As a growing brand trading at just 21 times this past year's earnings, investors may want to check this stock out.
The Motley Fool March 16, 2007 Rick Aristotle Munarriz	Bed Bugs at Select Comfort The Sleep Number bed maker holds the line in its mid-quarter update. Investors, take note.
The Motley Fool May 19, 2011 G. David Frye	Which Mattress Most Merits Your Investing Cash? Tempur-Pedic gives investors a better night's sleep.
The Motley Fool October 25, 2007 Rick Aristotle Munarriz	Select Comfort's Worst Nightmare Select Comfort lowers its guidance for the year in advance of quarterly earnings, while rival Tempur-Pedic beats estimates. Investors, take note.
The Motley Fool July 25, 2008 Rick Aristotle Munarriz	Never Take a Stock to Bed Select Comfort beats expectations, but it's all relative, because, on an absolute basis, the quarter was atrocious.
The Motley Fool October 25, 2006 Rick Aristotle Munarriz	Select Comfort's Air Ball The bed maker turns the knob higher, despite a rather ordinary start to the second half of the year. Investors, take note.
The Motley Fool August 1, 2008 Brian Lawler	Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug.
The Motley Fool April 5, 2005 Charly Travers	Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars.
The Motley Fool December 3, 2007 Ryan Fuhrmann	Fool on the Street: Sticker Shock at Conn's The electronics retailer may not be well-understood by certain investors, but it could prove an opportunity for others.
The Motley Fool February 5, 2007 Rich Smith	Foolish Forecast: Select Comfort Awakens The sleep number bed-maker is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool April 24, 2008 Rick Aristotle Munarriz	Select Comfort: No More Sheep to Count? Select Comfort has a rough night.
The Motley Fool November 30, 2006 Rick Aristotle Munarriz	Select Comfort Tosses and Turns The air-mattress maker proves mortal. Until comps resume their growing ways, there may not be a whole lot of life to these shares.
The Motley Fool October 31, 2006 Brian Lawler	A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware.
The Motley Fool October 21, 2010 Travis Hoium	A Rocket Stock for a Good Night's Sleep Select Comfort reported earnings that beat Wall Street estimates.
The Motley Fool December 19, 2011 Brian Orelli	Elan Turns It Around in 2011 Let's hope next year is as productive.
The Motley Fool January 18, 2011 Brian Orelli	Up 30%, Succeed Indeed! An aptly named clinical trial bodes well for Ariad Pharmaceuticals.
The Motley Fool August 10, 2005 Jack Uldrich	Does NanoCrystal Ball See All? There is promise in biotech Elan, but not for the reason you might think. Investors, take note.
The Motley Fool October 13, 2005 Seth Jayson	Dueling Fools: Select Comfort Bear Like the bed, the stock is overpriced. But the former will let you sleep well at night. Investors must remember that a product and a company are vastly different things.
The Motley Fool October 12, 2006 Rick Aristotle Munarriz	Dueling Fools: Select Comfort Bull Investors, sleep better at night with this company.
The Motley Fool October 25, 2007 Brian Lawler	Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation?
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
Chemistry World February 8, 2013 Andrew Turley	Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool October 13, 2005 W.D. Crotty	Dueling Fools: Select Comfort Bull Rebuttal It's the perfect bed to rest on, and that goes for your dollars, too. This is a great product, and the stock sells for a measly 17.9 times this year's low-end earnings guidance.
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool November 3, 2011 Sean Williams	Bash My Stock: Ariad Pharmaceuticals For those of you who've wondered what's wrong with your stock...
The Motley Fool January 2, 2012 Anders Bylund	What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012.
The Motley Fool August 30, 2007 Ryan Fuhrmann	Does Conn's Deserve Credit? Electronics retailer Conn's posts another solid quarter of sales and earnings growth, due in large part to its in-house financing program. Will current credit challenges derail its prospects?
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool October 20, 2009 Brian Orelli	All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug.
The Motley Fool June 15, 2005 Rich Duprey	Counting Sheep With Select Comfort's Numbers? Company says sales and revenues are on target, but it has a shoddy record of prognostication. Investors, take note.
The Motley Fool October 12, 2006 Chuck Saletta	Dueling Fools: Select Comfort Bear With Select Comfort's stock now trading in line with the largest public firm in the industry, future share price growth depends on operational growth that may not materialize. New shareholders simply cannot count on the success of the past to propel their holding forward in the future.
The Motley Fool December 13, 2007 Rick Aristotle Munarriz	Select Comfort Lets the Bed Bugs Bite Fitful mattress sales find Select Comfort withdrawing its guidance for both the current quarter and the year ahead, warning that the company will come up short relative to its own initial guidance.
The Motley Fool April 27, 2005 Rich Smith	Select Comfort's Q1 Lullaby The company's news lets Wall Street rest easy.
The Motley Fool April 25, 2007 Brian Lawler	Where Is Elan Going? Drugmaker Elan announces first-quarter financial results. Investors, take note.